Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Antitrust enforcement is likely to return to its established norms, Jay Ezrielev writes in a guest commentary.

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

As many as 18 constituents in the 30-scrip DJIA index succumbed to negative territory, with Cisco (down 2.5 per cent), ...

Over the last 10 months, the Congress government secured agreements for 140 Life Sciences or pharmaceutical projects ...

On Wednesday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $301.44 which represents a slight increase of $2.60 or 0.87% from the prior close of $298.84. The stock opened at $306 and ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...